Home > News > EntreMed Contracts With Elan to Produce Panzem(R) Clinical Material
July 13th, 2004
EntreMed Contracts With Elan to Produce Panzem(R) Clinical Material
EntreMed, Inc. today announced that it has entered into a Clinical Supply Agreement with Elan Drug Delivery, Inc. to reformulate and manufacture EntreMed's Panzem(R) in an oral liquid product format. This supply of reformulated Panzem(R) will support EntreMed's clinical oncology program that is planned to begin in early 2005. Elan is manufacturing the reformulated Panzem(R) using its proprietary NanoCrystal(R) technology that enhances product bioavailability and absorption and produces particles that are fifty times smaller than conventional processes.
MANA Research Highlight: Smart nanofibers to treat kidney failure March 6th, 2014
Harris & Harris Group, Inc. Establishes and Invests $350,001 in ProMuc, Inc. March 6th, 2014
First Look at How Individual Staphylococcus Cells Adhere to Nanostructures Could Lead to New Ways to Thwart Infections: Berkeley Lab-led research could guide the development of bacteria-resistant materials March 5th, 2014
Dartmouth Researchers Find Promising Results with Local Hyperthermia of Tumors March 4th, 2014